A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy And Safety Of Rivipansel (Gmi-1070) In The Treatment Of Vaso-occlusive Crisis In Hospitalized Subjects With Sickle Cell Disease
Phase of Trial: Phase III
Latest Information Update: 17 Dec 2017
At a glance
- Drugs Rivipansel (Primary)
- Indications Sickle cell anaemia
- Focus Registrational; Therapeutic Use
- Acronyms RESET
- Sponsors Pfizer
- 13 Nov 2017 Planned End Date changed from 17 Jul 2018 to 10 Jul 2018.
- 13 Nov 2017 Planned primary completion date changed from 17 Jul 2018 to 10 Jul 2018.
- 25 Oct 2017 Planned End Date changed from 10 Jul 2018 to 17 Jul 2018.